---
document_datetime: 2025-10-14 12:08:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_en.pdf
document_name: evusheld-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6559688
conversion_datetime: 2025-12-24 20:22:41.316796
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength        | Pharmaceutical Form    | Route of Administration   | Immediate Packaging         | Content (concentration)                 | Pack size       |
|------------------|-------------------|-----------------|------------------------|---------------------------|-----------------------------|-----------------------------------------|-----------------|
| EU/1/22/1651/001 | EVUSHELD          | 150 mg + 150 mg | Solution for injection | Intramuscular use         | vial (glass) + vial (glass) | 1.5 ml (100 mg/ml) + 1.5 ml (100 mg/ml) | 1 vial + 1 vial |

<!-- image -->